REG - IP Group PLC - Director Declaration

IPAnnouncement

25/11/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201125:nRSY3921Ga&default-theme=true

RNS Number : 3921G  IP Group PLC  25 November 2020

 FOR RELEASE ON  25 November 2020

 

Director Declaration

IP Group plc (LSE: IPO) ("the Group"), the developer of intellectual
property-based businesses, confirms that Elaine Sullivan, a non-executive
director of the Group, has been appointed as a director of Open Orphan plc and
Active Biotech AB. This disclosure is made in accordance with LR 9.6.14R of
the Listing Rules.

 

For more information, please contact:

 

 IP Group plc                                              www.ipgroupplc.com (http://www.ipgroupplc.com)
 Angela Leach, Company Secretary                           +44 (0) 20 7444 0050

Liz Vaughan-Adams, Communications
+44 (0) 20 7444 0062/+44 (0) 7979 853802

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which
focuses on evolving great ideas, mainly from its partner universities, into
world-changing businesses. The Group has pioneered a unique approach to
developing these ideas and the resulting businesses by providing access to
business building expertise, capital (through its 100%-owned FCA-authorised
subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and
business support. IP Group has a strong track record of success and its
portfolio comprises holdings in early-stage to mature businesses across life
sciences and technology. IP Group is listed on the Main Market of the London
Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com) .

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNKKQBDCBDDFDB